← GPCalc

NICE Heart Failure Calculator

NICE NG106 Chronic heart failure in adults: diagnosis and management (2025 update) · TA267, TA314, TA902, TA929, TA1182

Scenario

NT-proBNP

NICE-recommended plan

Choose suspected or confirmed heart failure and enter the details to see the plan.

Decision support only, based on NICE NG106 (2025 update) and linked technology appraisals. Doses are typical BNF/SPC starting and target doses – follow the specialist heart failure team's plan, local guidelines and the SPC. Acute or decompensated heart failure needs same-day assessment.

Quick reference

Diagnosis – NT-proBNP
NT-proBNPAction
>2,000 ng/L (>236 pmol/L)Specialist assessment + echo within 2 weeks (1.2.3)
400–2,000 ng/L (47–236 pmol/L)Specialist assessment + echo within 6 weeks (1.2.4)
<400 ng/LHeart failure less likely if untreated; review other causes; discuss with specialist if still concerned (1.2.5, 1.2.6)

Lowered by obesity, African/African-Caribbean background, diuretics, ACE inhibitors, ARBs, ARNIs, beta-blockers and MRAs. Raised by kidney, lung and liver disease, sepsis, COPD, diabetes (1.2.7).

Treatment by type
  • HFrEF (EF ≤40%): offer ACE inhibitor + beta-blocker + MRA + SGLT2 inhibitor (1.4.1). ACE intolerance (not angioedema) → ARNI instead (1.4.3). Angioedema or ARNI intolerance → consider ARB (1.4.4). All four at max and still symptomatic → consider ACE inhibitor to ARNI (1.4.2).
  • HFmrEF (EF 41–49%): consider ACE inhibitor (or ARB), beta-blocker, MRA (finerenone an option) and SGLT2 inhibitor (1.5.1–1.5.4).
  • HFpEF (EF ≥50% + structural change): consider MRA (finerenone an option) and SGLT2 inhibitor (1.5.5–1.5.7).
  • IV iron (HFrEF): Hb <150 g/L and TSAT <20% or ferritin <100 (1.4.6).
  • eGFR ≤45: lower starting doses, smaller steps (1.6.1).
Monitoring
  • U&E before ACE inhibitor/ARNI/ARB/MRA; 1–2 weeks after starting and each increase; every 3–6 months at max dose (1.7.3, 1.7.4).
  • Creatinine up >50% or K⁺ >5.5: follow local guidelines (1.7.5).
  • ECG before a beta-blocker; not if 2nd/3rd-degree block without pacemaker or HR <50 (1.7.10, 1.7.11).
  • Review at least 6-monthly when stable (1.8.3).